Most Read Articles
Kavitha G. Shekar, 04 May 2016
Cannabis use during pregnancy increases the risk of maternal anaemia, and causes several adverse outcomes in infants like low birth weight (LBW), and increased neonatal intensive care unit (NICU) admissions, show findings of a systematic review and meta-analysis.
26 Feb 2017
Placement of cervical pessary in women with short cervices and singleton pregnancies does not lower the risk of having preterm births, according to the results of a meta-analysis.
01 Jan 2015
Iron supplementation has long established its role from among women of child-bearing age. This study, however, looked into the effect of zinc when in combination with iron.
Roshini Claire Anthony, 07 Sep 2016

Estrogen receptor α (ESR1) mutations Y537S and D538G are associated with reduced overall survival (OS) in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, according to findings of a secondary analysis of the BOLERO-2* clinical trial.

Low pregnancy-associated plasma protein-A levels up risk of pre-eclampsia

6 days ago
It was speculated that the family’s wish for a second child in a short period of time might be the reason why they allegedly refused permission for a C-section delivery.

Low serum levels of pregnancy-associated plasma protein-A (PAPP-A) appears to increase the risk of early development pre-eclampsia, a recent study has shown.

The researchers performed a cohort study on 3,663 pregnant females with singleton pregnancies undergoing screening for foetal Down syndrome. In the cohort, 357 had low PAPP-A and were designated as the study group, while the remaining 3,306 were identified as controls. Maternal weight was significantly higher in the study vs control group (58.0±9.6 vs 53.5±8.0 kg; p<0.001).

In terms of pre-eclampsia, the prevalence rate was significantly higher in the study group compared with the control group (8.4 vs 2.6 percent; p<0.0001). Early-onset pre-eclampsia was also significantly more common in the study group (1.1 vs 0.1 percent; p=0.0016). The respective overall rates were 3.1 and 0.2 percent.

Risk analysis showed the same results. Those with lower serum PAPP-A levels had significantly elevated risks of pre-eclampsia (relative risk [RR], 3.27; 95 percent CI, 2.19–4.88) and early-onset pre-eclampsia (RR, 9.26; 2.33–36.87).

Low PAPP-A concentrations showed acceptable diagnostic indices, with a sensitivity of 26.1 percent and a specificity of 90.8 percent. The positive and negative predictive values were calculated to be 8.4 percent and 97.4 percent, respectively.

Decreased vs normal PAPP-A levels were also associated with other adverse birth outcomes, such as low birth weight (2,746±945 vs 3,035±526 g; p<0.001), stillbirth (9.5 percent vs 1.3 percent; p<0.0001), low Apgar scores (p<0.0001), preterm birth (16.2 percent vs 8.0 percent; p<0.0001) and foetal growth restrictions (10.9 percent vs 6.5 percent; p=0.002).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Kavitha G. Shekar, 04 May 2016
Cannabis use during pregnancy increases the risk of maternal anaemia, and causes several adverse outcomes in infants like low birth weight (LBW), and increased neonatal intensive care unit (NICU) admissions, show findings of a systematic review and meta-analysis.
26 Feb 2017
Placement of cervical pessary in women with short cervices and singleton pregnancies does not lower the risk of having preterm births, according to the results of a meta-analysis.
01 Jan 2015
Iron supplementation has long established its role from among women of child-bearing age. This study, however, looked into the effect of zinc when in combination with iron.
Roshini Claire Anthony, 07 Sep 2016

Estrogen receptor α (ESR1) mutations Y537S and D538G are associated with reduced overall survival (OS) in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, according to findings of a secondary analysis of the BOLERO-2* clinical trial.